Showing results (91-100 of 127) with videos related to
Sort By:
Pageof 13
The New England Journal of Medicine|December 21, 2007
Telbivudine versus lamivudine in patients with chronic hepatitis BChing-Lung Lai, Edward Gane, Yun-Fan Liaw, et al.Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.Gastroenterology|November 26, 2008
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis BYun-Fan Liaw, Edward Gane, Nancy Leung, et al.Gastroenterology|October 12, 2014
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantationMichael Charlton, Edward Gane, Michael P Manns, et al.The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist TherapyEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.The Lancet. Gastroenterology & Hepatology|February 16, 2024
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 studyThomas Yau, Ahmed Kaseb, Ann-Lii Cheng, et al.Journal of Hepatology|August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised studyScott Fung, Peter Kwan, Milotka Fabri, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.Open Forum Infectious Diseases|September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.Pageof 13